Mots $1.11 Awaiting news —> Motus said potential strategic alternatives, ranging from an acquisition, sale of assets and licensing, among others, is intended to position it to explore all alternatives, continue supporting existing customers using Pure-Vu EVS for colonoscopies, and target pipeline opportunities with contracted health systems.